Prostatic adenocarcinoma masquerading as generalized lymphadenopathy and mimicking lymphoma on FDG PET/CT: Diagnosis, staging, and evaluation of therapy response by FDG PET/CT

Nephro-Urology Monthly

Volumn 4, Issue 2, 2012, Pages 482-484

  Joshi, Prathamesh ^a   Lele, Vikram ^a  

^a JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

Author keywords

Adenocarcinoma; Hormone replacement therapy; Lymphatic diseases; Positron emission tomography; Prostate; Treatment response

Indexed keywords

BICALUTAMIDE; FLUORODEOXYGLUCOSE F 18; HORMONE; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; AXILLARY LYMPH NODE; BONE METASTASIS; CANCER DIAGNOSIS; CANCER STAGING; CASE REPORT; CERVICAL LYMPH NODE; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESPONSE; DYSURIA; ECHOGRAPHY; GLEASON SCORE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; LOW BACK PAIN; LYMPH NODE BIOPSY; LYMPHADENOPATHY; LYMPHOMA; MALE; METASTATIC PROSTATE ADENOCARCINOMA; ORCHIECTOMY; PARAAORTIC LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PROSTATE ADENOCARCINOMA; PROSTATE HYPERTROPHY; REMISSION; TRANSRECTAL ULTRASONOGRAPHY; URINARY TRACT DISEASE;

EID: 84858392900     PISSN: 22517006     EISSN: 22517014     Source Type: Journal    
DOI: 10.5812/numonthly.2303     Document Type: Article

References (11)

1. Woo K, Wieczorek R, Torre P, Lepor H. Prostate adenocarci-noma presenting as a large supraclavicular mass. Rev Urol. 2001;3(2):102-5.
2. Venable DD, Hastings D, Misra RP. Unusual metastatic patterns of prostate adenocarcinoma. J Urol. 1983;130(5):980-5.
3. Moura FM, Garcia LT, Castro LP, Ferrari TC. Prostate adenocarcinoma manifesting as generalized lymphadenopathy. Urol Oncol. 2006;24(3):216-9.
4. Butler JJ, Howe CD, Johnson DE. Enlargement of the supracla-vicular lymph nodes as the initial sign of prostatic carcinoma. Cancer. 1971;27(5):1055-63.
5. Fernandes H, Naik C, Marla N, Arora D. Supraclavicular lymphadenopathy-initial manifestation of prostatic carcinoma. J Cytol. 2007;24(3):157.
6. Wang HJ, Chiang PH, Peng JP, Yu TJ. Presentation of prostate carcinoma with cervical lymphadenopathy: report of three cases. Chang Gung Med J. 2004;27(11):840-4.
7. Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol. 1999;36(1):31-5.
8. Effert PJ, Bares R, Handt S, Wolff JM, Bull U, Jakse G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol. 1996;155(3):994-8.
9. Oyama N, Akino H, Kanamaru H, Okada K. [Fluorodeoxyglucose positron emission tomography in diagnosis of untreated prostate cancer]. Nihon Rinsho. 1998;56(8):2052-5.
10. Oyama N, Akino H, Suzuki Y, Kanamaru H, Ishida H, Tanase K, et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Commun. 2001;22(9):963-9.
11. Papatsoris AG, Mpadra FA, Karamouzis MV. Prostate cancer presenting as a solitary cerebellar metastasis. A case report and review of the literature. Tumori. 2002;88(1):61-4.